Last edition
News about "VIVID-2"
Eli Lilly's Omvoh Shows Long-Term Efficacy in Crohn's Disease: VIVID-2 Study Results Announced
Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.
VIVID-2 | 07/02/2025 | By Abha
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members